Einrichtungen Einrichtung-Details

Klinik für Urologie und Kinderurologie - Ruppiner Kliniken

Link zur Website der Klinik für Urologie und Kinderurologie

Wissenschaftliche Schwerpunkte

Keine laufenden Projekte

Ausgewählte Publikationen

Wolff I, May M, Hoschke B, Gilfrich C, Peter J, Ecke T, Schostak M, Lebentrau S. [Differences between the inpatient complication rate after ureterorenoscopy and the 30-day outcome reported by the patient - results of the German prospective BUSTER study]. Aktuelle Urol. 2018.

May M, Schostak M, Lebentrau S, MR2- study group. Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: a call for its implementation in clinical routine. Int Urogynecol J. 2018.

Lebentrau S, Enzmann T, Lehsnau M, Christoph F, Schostak M, May M, BUSTER study group. Hospital volume in ureterorenoscopic stone treatment: 99 operations per year could increase the chance of a better outcome-results of the German prospective multicentre BUSTER project. World J Urol. 2018.

Wolff I, Lebentrau S, Miernik A, Ecke T, Gilfrich C, Hoschke B, Schostak M, May M, BUSTER study group. Impact of surgeon's experience on outcome parameters following ureterorenoscopic stone removal. Urolithiasis. 2018.

May M, Schönthaler M, Gilfrich C, Wolff I, Peter J, Miernik A, Fritsche HM, Burger M, Schostak M, Lebentrau S, BUSTER-Arbeitsgruppe. [Interrater reliability and clinical impact of the Post-Ureteroscopic Lesion Scale (PULS) grading system for ureteral lesions after ureteroscopy: Results of the German prospective multicenter BUSTER project]. Urologe A. 2018;57(2):172-180.

Roiner M, Maurer O, Lebentrau S, Gilfrich C, Schäfer C, Haberl C, Brookman-May SD, Burger M, May M, Hakenberg OW. [Management of penile cancer patients: new aspects of a rare tumour entity]. Aktuelle Urol. 2018;49(3):242-249.

Christoph F, König F, Lebentrau S, Jandrig B, Krause H, Strenziok R, Schostak M. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease. World J Urol. 2018;36(2):187-192.

Lebentrau S, Gilfrich C, Vetterlein MW, Schumacher H, Spachmann PJ, Brookman-May SD, Fritsche HM, Schostak M, Wagenlehner FM, Burger M, May M. Re: Letter to the editor. Int Urol Nephrol. 2018;50(5):875.

Lebentrau S, Müller PF, Miernik A, Schönthaler M, Gilfrich C, Peter J, Schostak M, May M, BUSTER study group. Risk Factors for Ureteral Damage in Ureteroscopic stone Treatment: Results of the German Prospective Multicentre Benchmarks of Ureterorenoscopic Stone Treatment-Results in Terms of Complications, Quality of Life, and Stone-Free Rates Project. Urol Int. 2018;1-7.

Lebentrau S, May M, Ziegler H, Werthemann P, Enzmann T, Schostak M, Porsch M, BUSTER-Studiengruppe. [The recommendations of the S2k guideline for the diagnosis, therapy and metaphylaxis of urolithiasis provide a safe course of action for ureterorenoscopic stone treatment - results of the BUSTER study]. Aktuelle Urol. 2018;49(2):164-170.

Christoph F, König F, Lebentrau S, Blaschke S, Liehr UB, Schostak M. [Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]. Aktuelle Urol. 2018;49(2):157-163.